4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Lewy Body Dementia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 37 ongoing clinical trials involving Lewy Body Dementia
Of the 37 trials,17 trials are in Phase III
Furthermore, 15 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Lewy Body Dementia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Lewy Body Dementia, a Central Nervous System condition. The largest number of ongoing clinical trials for Lewy Body Dementia is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Lewy Body Dementia-related drug trials.

Georgetown University: The leading ongoing Lewy Body Dementia-related clinical trial sponsor

Georgetown University is the top sponsor for Lewy Body Dementia-related ongoing clinical trials.

Neurimmune Holding AG, Inha University Hospital, California Pacific Medical Center Research Institute, Aptinyx Inc, and Zealand University Hospital are among other notable clinical trial sponsors involved in Lewy Body Dementia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Lewy Body Dementia

Donepezil hydrochloride (Aricept, Donepezil, E2020) and Zonisamide (Zonegran, Excegran, Trerief) are among the key marketed drugs involving Lewy Body Dementia.

Donepezil hydrochloride (Aricept, Donepezil, E2020) is a piperidine derivative that acts as an anti-dementia agent. It functions via Acetylcholinesterase Inhibitor mechanism of action. It is formulated as film-coated tablets and tablets for the oral route of administration. Aricept is indicated for the treatment of dementia of the Alzheimer’s type and Lewy body dementia. The drug candidate is under development for visuospatial dysfunction in patients with mild cognitive impairment. It was also under development for the treatment of attention deficit hyperactivity disorder, down syndrome, vascular dementia, and migraine prophylaxis. Donepezil hydrochloride was first approved in 1996 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Eisai Inc.

Zonisamide (Zonegran, Excegran, Trerief) is a benzoxazole that acts as an anti-seizure, antiparkinson agent. It functions via Voltage-Dependent Calcium Channel Blocker; Voltage-Gated Sodium Channel (SCN) Blocker mechanism of action. It is formulated as capsules and film coated tablets for the oral route of administration. Zonegran and Excegran are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Trerief is indicated for the treatment of Parkinsonism in dementia with Lewy bodies (DLB). Zonisamide was first approved in 1989 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Sunovion Pharmaceuticals Inc.